Why I’d ditch this defensive dividend stock to buy AstraZeneca plc

G A Chester argues AstraZeneca plc (LON:AZN) is the pick of two defensive dividend stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Dairy Crest (LSE: DCG) today reported a “strong first half of the year” in a pre-close trading update for the six months to 30 September. Management said it expects combined volumes of its four key brands — Cathedral City, Clover, Country Life and Frylight — to be ahead of the same period last year, with group profit also ahead. It added: “Our profit expectations for the full year are unchanged.”

The shares are trading up 1.6% at 616p, as I’m writing, putting the FTSE 250 firm on a forward price-to-earnings (P/E) ratio of 16.4, with a prospective dividend yield of 3.7%. This valuation looks quite attractive for a company in the defensive food producers sector but I see greater attraction in a similarly rated stock in another defensive sector.

At a share price of 4,700p, AstraZeneca (LSE: AZN) trades on a forward P/E of 16.8, with a prospective dividend yield of 4.4%. If I needed to free-up funds to invest in the FTSE 100 pharma giant, I’d be willing to sacrifice Dairy Crest.

Revenues and profits

AstraZeneca’s revenue has fallen from $28bn to $23bn over the last five years, as patent expiries on some of its top-selling products have taken a toll. Meanwhile, Dairy Crest’s revenue has declined more modestly from £430m to £417m (after stripping out its Dairies operation, which it sold in 2015).

Top-line growth is essential for profit growth in the long run and the good news is that Dairy Crest’s revenue is forecast to begin increasing from this year and AstraZeneca’s from next year. Even if the pharma group falls short of chief executive Pascal Soriot’s ambitious target of $45bn in annual revenues by 2023 — as its strong pipeline of new drugs begins to bear fruit — I expect it to comfortably outpace the top-line growth of Dairy Crest.

The vast majority of Dairy Crest’s revenues come from the mature UK market but it’s diversification into supplying ingredients for infant formula — a high-growth, high-margin global market — should help profits move higher. Nevertheless, I reckon AstraZeneca’s cost-base restructuring of the last few years should lead to superior profit advances as its top-line growth kicks in.

Dividends and debt

Dairy Crest has increased its dividend — if rather unspectacularly — from 20.7p to 22.5p over the last five years. However, its net debt has increased from £60m to £249m during the period, giving sky-high gearing of 346%. Furthermore, despite its defensive qualities, it rebased its dividend 25% lower back in 2009.

By contrast, AstraZeneca has managed to maintain its dividend at 280 cents over the past five years of protracted pressure on revenues and profits. Its net debt has also risen (from $1.4bn to $10.7bn) but gearing is a far more comfortable 72%.

If my top- and bottom-line growth expectations for AstraZeneca are on the mark, it should be capable of providing a superior dividend return in due course, particularly from a current starting yield of 4.4% versus Dairy Crest’s 3.7%

Other qualities

Finally, Dairy Crest not only has far more limited geographical diversification than AstraZeneca, but also higher customer-concentration risk. Almost half its revenue comes from just three customers.

This contrasts with its larger and more diversified food producer peer Unilever, which has no single customer accounting for 10% or more of its revenue. And like Unilever, AstraZeneca has a wide diversity of customers and suppliers across different geographic areas. Only one wholesaler accounts for greater than 10% of its product sales.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »